Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 10/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1760399 | 0.81 | KCNA5 (0.52) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL11870135 | 0.72 | LMNA (0.54) | TP53SMN1; SMN2ACHECA12CA1 | |
| SCHEMBL11443225 | 0.72 | KCNA5 (0.57) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL6867863 | 0.72 | MAPT (0.50) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL16259070 | 0.71 | KCNA5 (0.56) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL2946729 | 0.71 | KCNA5 (0.64) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL9828963 | 0.70 | KCNA5 (0.55) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL7145304 | 0.70 | KCNA5 (0.48) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL2768711 | 0.69 | KCNA5 (0.54) | EPHX2KCNA5TP53SMN1; SMN2ACHE | |
| SCHEMBL6991890 | 0.69 | EPHX2 (0.44) | EPHX2KCNA5TP53SMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| EP-2195029-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | Oryzon Genomics SA (ES) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009027349-A2 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS SA (ES) | 2009-03-05 | — | — | WO | disclosed |
| US-20070197610-A1 | Benzisoxazoles | JANSSEN PHARMACEUTICA N.V. | 2007-08-23 | — | — | US | disclosed |
| EP-0669920-B1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | AVENTIS PHARMA INC (US) | 2003-02-12 | — | — | EP | disclosed |
| US-5925766-A | COGNITION ACTIVATORS FOR DECREASING CHOLINERGIC FUNCTION OF ALZHEIMER*S DISEASE AND ARE ENZYME INHIBITORS OF MONOAMINE OXIDASE AND ARE ANTIDEPRESSANTS | HOECHST MARION ROUSSEL, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5756754-A | Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds | HOECHST MARION ROUSSEL, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| US-5580982-A | ANTIDEPRESSANTS; ANTICHOLINERGIC AGENTS; ALZHEIMER'S DISEASE; AMINE OXIDASE INHIBITORS | HOECHST MARION ROUSSEL INC. (US) | 1996-12-03 | — | — | US | disclosed |
| US-5494908-A | ANTIDEPRESSANT | HOECHST-ROUSSEL PHARMACEUTICAL INCORPORATED (US) | 1996-02-27 | — | — | US | disclosed |
| EP-0669920-A4 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS. | HOECHST ROUSSEL PHARMA (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0669920-A4 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS. | HOECHST ROUSSEL PHARMA (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0669920-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST MARION ROUSSEL, Inc. (US) | 1995-09-06 | — | — | EP | disclosed |
| EP-0669920-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST MARION ROUSSEL, Inc. (US) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994012495-A1 | SUBSTITUTED 3-(AMINOALKYLAMINO)-1,2-BENZISOXAZOLES AND RELATED COMPOUNDS | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1994-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197610-A1 | Benzisoxazoles | NR4A1, OXER1, NR0B1 | EPHX2 533/4885KCNA5 813/4885TP53 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.